CA2480425A1 - Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation - Google Patents
Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation Download PDFInfo
- Publication number
- CA2480425A1 CA2480425A1 CA002480425A CA2480425A CA2480425A1 CA 2480425 A1 CA2480425 A1 CA 2480425A1 CA 002480425 A CA002480425 A CA 002480425A CA 2480425 A CA2480425 A CA 2480425A CA 2480425 A1 CA2480425 A1 CA 2480425A1
- Authority
- CA
- Canada
- Prior art keywords
- liquid preparation
- glycyl
- group
- preparation according
- glycine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002112864 | 2002-04-16 | ||
| JPNO.2002-112864 | 2002-04-16 | ||
| PCT/JP2003/004745 WO2003086471A2 (en) | 2002-04-16 | 2003-04-15 | Lyophilized and liquid preparations comprising a polysaccharide derivative of camptothecin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2480425A1 true CA2480425A1 (en) | 2003-10-23 |
Family
ID=29243336
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002480425A Abandoned CA2480425A1 (en) | 2002-04-16 | 2003-04-15 | Liquid preparation comprising camptothecin derivative and pharmaceutical composition producible by lyophilizing the preparation |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US20050215485A1 (enExample) |
| EP (1) | EP1501549A2 (enExample) |
| JP (1) | JP3927954B2 (enExample) |
| KR (1) | KR100700963B1 (enExample) |
| CN (1) | CN100544769C (enExample) |
| AR (1) | AR039272A1 (enExample) |
| AU (1) | AU2003223120B2 (enExample) |
| BR (1) | BR0309283A (enExample) |
| CA (1) | CA2480425A1 (enExample) |
| HR (1) | HRP20040894A2 (enExample) |
| ME (1) | MEP31308A (enExample) |
| MX (1) | MXPA04010178A (enExample) |
| MY (1) | MY136696A (enExample) |
| NO (1) | NO20044964L (enExample) |
| PL (1) | PL371677A1 (enExample) |
| RS (1) | RS91204A (enExample) |
| RU (1) | RU2315623C2 (enExample) |
| TW (1) | TW200306314A (enExample) |
| UA (1) | UA77295C2 (enExample) |
| WO (1) | WO2003086471A2 (enExample) |
| ZA (1) | ZA200408008B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1714653B1 (en) * | 2004-02-13 | 2010-11-24 | Kabushiki Kaisha Yakult Honsha | Aqueous solution preparation containing a camptothecin |
| US20070207149A1 (en) | 2004-04-27 | 2007-09-06 | Wellstat Biologics Corporation | Cancer treatment using viruses and camptothecins |
| CA2612949C (en) | 2005-07-14 | 2015-04-28 | Wellstat Biologics Corporation | Cancer treatment using viruses, fluoropyrimidines and camptothecins |
| JP2007260275A (ja) * | 2006-03-29 | 2007-10-11 | Transcutaneous Technologies Inc | イオントフォレーシス装置及びイオントフォレーシス投与用組成物 |
| WO2011041003A2 (en) | 2009-06-22 | 2011-04-07 | Wyeth Llc | Compositions and methods for preparing staphylococcus aureus serotype 5 and 8 capsular polysaccharide conjugate immunogenic compositions |
| AU2010264538B2 (en) | 2009-06-22 | 2013-10-03 | Wyeth Llc | Immunogenic compositions of Staphylococcus aureus antigens |
| CN102764260B (zh) * | 2011-04-30 | 2014-07-30 | 正大天晴药业集团股份有限公司 | 一种喜树碱衍生物的药物组合物及其制备方法 |
| WO2013011598A1 (ja) * | 2011-07-15 | 2013-01-24 | コニカミノルタホールディングス株式会社 | 溶解助剤を利用したリポソーム含有製剤およびその製造方法 |
| CN113304278A (zh) | 2014-12-26 | 2021-08-27 | 日本化药株式会社 | 喜树碱类高分子衍生物的药物制剂 |
| RU2726415C2 (ru) | 2015-09-03 | 2020-07-14 | Ниппон Каяку Кабусики Каися | Фармацевтическая композиция, содержащая полимерное производное камптотецина |
| US10517961B2 (en) | 2015-09-25 | 2019-12-31 | ZY Therapeutics, Inc. | Drug formulation based on particulates comprising polysaccharide-vitamin conjugate |
| RU2018129760A (ru) * | 2016-03-01 | 2020-04-01 | Ниппон Каяку Кабусики Кайся | Фармацевтический препарат, содержащий полимерное производное на основе камптотецина |
| CN109481691A (zh) * | 2018-11-20 | 2019-03-19 | 珠海天香苑生物科技发展股份有限公司 | 吉西他滨-羧甲基多糖共轭物、制备方法及其用途 |
| MX2024006239A (es) * | 2021-11-26 | 2024-06-11 | Astellas Pharma Inc | Composicion farmaceutica solida que contiene el compuesto indocianina. |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5340817A (en) * | 1987-04-14 | 1994-08-23 | Research Triangle Institute | Method of treating tumors with anti-tumor effective camptothecin compounds |
| DK0540099T3 (da) * | 1991-10-29 | 1996-06-17 | Glaxo Wellcome Inc | Vandopløselige camptothecinderivater |
| SG50747A1 (en) * | 1995-08-02 | 1998-07-20 | Tanabe Seiyaku Co | Comptothecin derivatives |
| IT1282673B1 (it) * | 1996-02-23 | 1998-03-31 | Ist Naz Stud Cura Dei Tumori | Derivati della camptotecina e loro uso come agenti antitumorali |
| TW527183B (en) * | 1996-06-06 | 2003-04-11 | Daiichi Seiyaku Co | Drug complex |
| US6288072B1 (en) * | 1999-12-29 | 2001-09-11 | Monroe E. Wall | Camptothecin β-alanine esters with topoisomerase I inhibition |
| AR030207A1 (es) * | 2000-04-07 | 2003-08-13 | Daiichi Seiyaku Co | Composicion farmaceutica que contiene un derivado de camptotecina y procedimiento de preparacion de la misma |
| AU2001271037A1 (en) * | 2000-07-13 | 2002-01-30 | Daiichi Pharmaceutical Co., Ltd. | Pharmaceutical compositions containing dds compounds |
| TWI313609B (en) * | 2001-08-21 | 2009-08-21 | Mitsubishi Tanabe Pharma Corp | Pharmaceutical composition for inhibiting the metastasis or preventing the recurrence of malignant tumor |
-
2003
- 2003-04-01 TW TW092107354A patent/TW200306314A/zh unknown
- 2003-04-09 AR ARP030101238A patent/AR039272A1/es unknown
- 2003-04-11 MY MYPI20031367A patent/MY136696A/en unknown
- 2003-04-15 CA CA002480425A patent/CA2480425A1/en not_active Abandoned
- 2003-04-15 PL PL03371677A patent/PL371677A1/xx not_active Application Discontinuation
- 2003-04-15 ME MEP-313/08A patent/MEP31308A/xx unknown
- 2003-04-15 JP JP2003587152A patent/JP3927954B2/ja not_active Expired - Fee Related
- 2003-04-15 BR BR0309283-6A patent/BR0309283A/pt not_active IP Right Cessation
- 2003-04-15 HR HR20040894A patent/HRP20040894A2/xx not_active Application Discontinuation
- 2003-04-15 KR KR1020047016514A patent/KR100700963B1/ko not_active Expired - Fee Related
- 2003-04-15 RU RU2004133349/15A patent/RU2315623C2/ru not_active IP Right Cessation
- 2003-04-15 AU AU2003223120A patent/AU2003223120B2/en not_active Ceased
- 2003-04-15 WO PCT/JP2003/004745 patent/WO2003086471A2/en not_active Ceased
- 2003-04-15 US US10/509,912 patent/US20050215485A1/en not_active Abandoned
- 2003-04-15 EP EP03719110A patent/EP1501549A2/en not_active Withdrawn
- 2003-04-15 CN CNB038082292A patent/CN100544769C/zh not_active Expired - Fee Related
- 2003-04-15 MX MXPA04010178A patent/MXPA04010178A/es active IP Right Grant
- 2003-04-15 UA UA20041109367A patent/UA77295C2/uk unknown
- 2003-04-15 RS YU91204A patent/RS91204A/sr unknown
-
2004
- 2004-10-05 ZA ZA200408008A patent/ZA200408008B/en unknown
- 2004-11-15 NO NO20044964A patent/NO20044964L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR100700963B1 (ko) | 2007-03-28 |
| AU2003223120A1 (en) | 2003-10-27 |
| EP1501549A2 (en) | 2005-02-02 |
| UA77295C2 (en) | 2006-11-15 |
| AU2003223120B2 (en) | 2006-10-05 |
| BR0309283A (pt) | 2005-02-15 |
| WO2003086471A2 (en) | 2003-10-23 |
| US20050215485A1 (en) | 2005-09-29 |
| PL371677A1 (en) | 2005-06-27 |
| AU2003223120A2 (en) | 2003-10-27 |
| KR20050000516A (ko) | 2005-01-05 |
| AR039272A1 (es) | 2005-02-16 |
| NO20044964L (no) | 2004-11-15 |
| MY136696A (en) | 2008-11-28 |
| JP2005523329A (ja) | 2005-08-04 |
| RU2004133349A (ru) | 2005-05-27 |
| RU2315623C2 (ru) | 2008-01-27 |
| HRP20040894A2 (en) | 2005-10-31 |
| CN1646172A (zh) | 2005-07-27 |
| MXPA04010178A (es) | 2005-06-08 |
| JP3927954B2 (ja) | 2007-06-13 |
| TW200306314A (en) | 2003-11-16 |
| RS91204A (sr) | 2006-12-15 |
| ZA200408008B (en) | 2005-06-13 |
| CN100544769C (zh) | 2009-09-30 |
| WO2003086471A3 (en) | 2004-04-15 |
| MEP31308A (en) | 2010-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101502533B1 (ko) | 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법 | |
| AU2003223120B2 (en) | Lyophilized and liquid preparations comprising a polysaccharide derivative of camptothecin | |
| KR20040074099A (ko) | Ｅｇｆ 수용체에 대한 항체를 함유하는 동결건조된 제제 | |
| WO2007095850A1 (en) | A pharmaceutical composition of docetaxel, preparation and use | |
| AU2003235401A1 (en) | Medicinal compositions containing ghrelin | |
| JP2006137678A (ja) | インターロイキン−２組成物 | |
| EA036982B1 (ru) | Способ получения лиофилизированной фармацевтической композиции, содержащей митомицин с | |
| EP3062883A1 (en) | Stable compositions of peptide epoxy ketones | |
| JP4142149B2 (ja) | バンコマイシンの凍結乾燥製剤 | |
| JPH05331071A (ja) | カルシトニン遺伝子関連ペプチド類の凍結乾燥組成物および安定化法 | |
| US20220000792A1 (en) | Albumin pharmaceutical composition and preparation method therefor | |
| US12564619B2 (en) | Stable formulations of recombinant proteins | |
| CA2809646C (en) | 5.alpha.-androstane-3.beta.,5,6.beta.-triol injection and preparation method therefor | |
| KR20070084150A (ko) | 세팔로스포린 유도체를 위한 안정화된 동결건조 제형물 | |
| US12491229B2 (en) | Stabilized peptide composition | |
| US11957758B2 (en) | Pharmaceutical composition of docetaxel conjugate and preparation method | |
| ITMI942166A1 (it) | Composizioni farmaceutiche miorilassanti | |
| WO2022265591A1 (en) | Pharmaceutical compositions of bevacizumab | |
| JPH08231398A (ja) | 凍結乾燥製剤 | |
| US20030139468A1 (en) | Amiodarone solutions suitable for intravenous administration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Dead |